Current HCV Treatment:  FDA approved medications to treat hepatitis C, side effect management, disease progression after successful treatment, and treatment of various populations of people with hepatitis C.

 

·        Disease Progression

o       LB9. Sustained Virologic Response Is Associated with Eradication of Hepatitis C Virus and Fibrosis Regression in Patients Treated for Chronic Hepatitis C (updated November 8, 2006)

o       337. Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following sustained virologic response (SVR) to HCV therapy: a prospective 5 year cohort study (updated October 28, 2006)

o       377. The risk of hepatocellular carcinoma and decompensation following hepatitis C treatment with interferon based therapy

o       403. Improvement in immunological abnormalities in patients with chronic hepatitis C who have a sustained virological response to therapy (updated October 28, 2006)

 

·        Drug users

o       88. Integrated Drug and HCV Treatment for Street-Recruited Heroin Users

o       370. Hepatitis C screening and treatment among drug users in Amsterdam: interim results of the inclusion procedure in the Dutch C project (updated October 31, 2006)

o       374. Overcoming barriers to treatment of hepatitis C in Italian drug users. The importance of a co-management model of care

o       375. Successful hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants (updated October 28, 2006)

o       396. Substitute opiate use in intravenous drug users (IVDUs) does not adversely effect sustained virological response(SVR) following treatment of chronic hepatitis C (CHC) with pegylated interferon alpha (PEG- IFN) and ribavirin (updated November 3, 2006)

o       399. Managing HCV infection in injecting drug users: a community model (updated November 8, 2006)

 

·        General

o       85. The primary transcriptional response to pegylated IFN-α2a and -α2b is correlated with the clinical outcome in patients with chronic hepatitis C

o       247. Detection of low amounts of HCV-RNA in the serum of sustained virological responders after antiviral therapy (updated October 28, 2006)

o       332. The Nonstructural 5A (NS5A) Protein of Hepatitis C Virus Genotype 1b Does Not Contain an “Interferon Sensitivity Determining Region”

o       346. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise “super-responders” (updated October 28, 2006)

o       351. Treatment with peg-interferon and ribavirin therapy in dialysis patients with chronic hepatitis C (updated October 28, 2006)

o       356. Development of HCC in Patients who Achieve SVR to IFN-Based Therapies is Associated with Cirrhosis and Prior HBV Exposure (updated November 8, 2006)

o       359. Therapy A la Carte Is More Cost-Effective Than Standard Combination Therapy For Naive Patients With Chronic Hepatitis C (updated November 1, 2006)

o       361. Re-infection following successful treatment for Hepatitis C virus Infection with either alpha interferon or pegylated interferon/ribavirin combination therapy (updated November 3, 2006)

o       364. Predictors of relapse and of sustained virologic response in patients with HCV genotype 3 with and without HIV co-infection: basis for an “a la carte” treatment

o       371. Pegylated interferon and ribavirin in haemodialyzed patients with chronic hepatitis C: a prospective study (updated October 28, 2006)

o       376. Late treatment of chronic hepatitis C in renal transplant recipients : an open pilot study (updated October 28, 2006)

o       378. Maintenance pegylated IFN given once every three weeks prevents relapse of hepatitis C virus (HCV) in decompensated cirrhosis (updated October 28, 2006)

o       382. Assessment of Th1 and Th2 cytokines during antiviral therapy for HCV Mixed Cryoglobulinemia

o       386. Efficacy and safety of IFN treatment for the 70 year-old or over patients with chronic hepatitis C

o       389. Antiviral therapy for HCV-associated mixed cryoglobulinemia vasculitis : a long term follow-up (updated October 28, 2006)

o       397. Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis C Treated in Daily Clinical Practice (updated October 28, 2006)

o       398. Plasma ribavirin quantification in patients with chronic hepatitis C, genotype 1, treated with peginterferon and ribavirin

o       400. Pegylated interferon plus ribavirin in chronic hepatitis C patients with liver lesions related to alcohol intake (updated October 28, 2006)

o       402. The Therapeutic Effect of Ribavirin plus Pegylated Interferon in Chronic Hepatitis B and C

o       408. Mutagenic effect of ribavirin on NS5B quasispecies heterogeneity in vitro and in patients with chronic hepatitis C

o       409. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon

o       425. Rapid Decline of Hepatitis C Viral (HCV) RNA and Very Early Virologic Responses (VEVR) Are Associated With Low Sequence Diversity in the NS5A Region

o       1124. Predictors Of Rapid Virologic Response (Rvr) In Hcv Genotype 1 Chronic Infected Pts: Results Of A Randomized Controlled Trial On Individualized Treatment

o       1125. Peripheral blood gene expression profiles predict sustained virologic response following peginterferon and ribavirin therapy

o       1126. Hepatitis C virus directly causes insulin resistance independent of the visceral adipose tissue area in non-obese and non-diabetic Japanese patients (disease progression – metabolic syndromes (updated October 31, 2006)

o       1139. Effect of sustained response in the incidence of type 2 diabetes mellitus in chronic hepatitis C

 

·        Infergen

o       1128. Extended Treatment of 72 versus 48 Weeks for Chronic Hepatitis C Patients with Genotype 1 and High Viral Load using Daily Consensus Interferon and Ribavirin (updated October 31, 2006)

o       1129. Treatment of Hepatitis C Patients with Child A and B Cirrhosis with Consensus Interferon and Ribavirin in a Low Ascending Dosing Regimen Leads to Significant Viral Elimination Rates (updated October 31, 2006)

 

·        Methadone

o       363. Therapeutic Efficacy of 24 Weeks’ Antiviral Treatment in Addicted Patients on Methadone Maintenance Therapy Who Have Chronic Hepatitis C, Genotype 1, With Low Baseline Viremia

 

·        Pegasys

o       2. A Randomized Controlled Trial of Prophylactically Administered Peginterferon Alfa-2a Plus Ribavirin vs No Prophylaxis Following Orthotopic Liver Transplantation (OLT) for Hepatitis C: A Report of Initial Safety and Tolerability

o       4. Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report

o       86. Changes in body weight and insulin sensitivity during and after peginterferon and ribavirin therapy of chronic hepatitis C

o       208. A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection.

o       209. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®).

o       335. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV)(COPEGUS®) in patients with “difficult-to-cure” characteristics. (updated November 1, 2006)

o       340. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alfa-2a (40KD) plus ribavirin: findings from ACCELERATE (updated November 1, 2006)

o       342. Effect of drug exposure on sustained virological response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks (updated October 28, 2006)

o       350. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin (updated October 28, 2006)

o       353. Efficacy and safety of peginterferon alfa-2a administrated every five days in combination with ribavirin in hcv genotype 1-infected patients with severe fibrosis not responding to weekly administrations of peginterferon in combination with ribavirin (updated October 31, 2006)

o       365. The PRESCO trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C  (updated November 1, 2006)

o       368. Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (PEGASYS) plus ribavirin: Improving differentiation between low (LVL) and high baseline viral load (HVL) (updated October 28, 2006)

o       380. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in HCV patients with complete cirrhosis (Knodell score F4) (updated October 28, 2006)

o       381. Effect of hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks (updated October 28, 2006)

o       388. Exposure to ribavirin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection: analysis of the Canadian Pegasys Expanded Access Program (EAP) (updated November 8, 2006)

o       390. Customizing treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with HCV genotype 1 or 4 infection. Interim results of a prospective randomized trial (updated November 8, 2006)

o       392. Treatment of subjects with chronic hepatitis C infection (HCV) and end stage renal disease (ESRD) using low dose pegylated interferon alpha 2 a (PEG-IFN) and Ribavirin (RBV) (updated November 8, 2006)

o       395. Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day (updated October 28, 2006)

o       669. Impact of Hepatitis C Virus (HCV) Infection in Children: Quality of Life, Emotional, and Cognitive Outcomes

o       1123. HCV RNA Negativity After 12 Weeks of Therapy is the Best Predictor of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon-α/Ribavirin Non-Responders (NR): Results from the EPIC3  Program (updated November 1, 2006)

o       1137. Comparison of a 24 -week standard combination therapy with PEG-IFN-α2a/Ribavirin with a 12-week monotherapy with PEG-IFN-α2a followed by a 12 week standard combination with Peg-IFN-α2a/Ribavirin in Hepatitis C infected patients with genotype 2 or 3 (updated October 31, 2006)

 

o       Pegasys - Cirrhosis

§        330. Treatment of Cirrhotic Patients with HCV Referred for Liver Transplantation Using an Escalating Dose Regimen of Pegylated Interferon Alpha-2a and Ribavirin (updated October 28, 2006)

 

o       Pegasys - Side effects

§        331. Identification of candidate genes that mediate depressive side effects of pegylated IFN-αlpha 2a in patients with chronic hepatitis C

 

·        Peg-Intron

o       3. Long-term Histological Effects of Preemptive Antiviral Therapy in Liver Transplant Recipients with Hepatitis C Virus (HCV) Infection

o       87. Gene expression involving interferon-regulatory innate immunity and resistance to PEG-interferon alfa-2b plus ribavirin treatment in chronic hepatitis C

o       90. Sustained dysfunction of dendritic cells as a predictor for relapse in chronic hepatitis C patients who underwent 48-week pegylated interferon-α and ribavirin therapy

o       338. Pegylated interferon alfa 2 b + ribavirin are equally efficacious and well tolerated in patients >65 years old in comparison to other age groups: Subanalysis of a randomized, controlled study (WIN-R Trial) (updated October 28, 2006)

o       339. A prospective, multicenter, observational study on compliance with viral hepatitis C treatments (CHEOBS study) (updated November 8, 2006)

o       343. Improved Virologic Response Rates With Treatment Extension To 72 Weeks Of Peginterferon Alfa-2B Plus Weight-Based Ribavirin In A Difficult-To-Treat Population Of Genotype 1-Infected Slow Responders (updated October 28, 2006)

o       349. Prospective Analysis of Sustained Virologic Response (SVR) to Peg-interferon (PEG IFN) Alfa-2b and Ribavirin Treatment in Asian and Hispanic Patients with Chronic Hepatitis C: Results from the WIN-R Trial (updated October 28, 2006)

o       352. IL-10 levels during treatment with PegIFN-alpha 2b and Ribavirin in patients with Chronic Hepatitis C of different genotypic constitution

o       358. An Interim Analysis of the Canadian POWeR Program (Peginterferon alfa-2b Prospective Optimal Weight-Based Dosing Response): Consistent SVR Rates Across All Weight Categories (updated October 28, 2006)

o       369. Response to Peginterferon Alfa-2b and Ribavirin for Chronic Hepatitis C in Patients with Body Weight >125 kg: Results from the WIN-R Trial (updated October 28, 2006)

o       372. Economic Evaluation of Individualized versus Standard Treatment Approach for Patients with Chronic Hepatitis C Virus Genotype-1 (G1) Low Viral Load (LVL) Using Peginterferon Alpha-2b Plus Ribavirin in the United Kingdom (updated November 8, 2006)

o       383. Standard and Pegylated Interferon alfa-2b plus Ribavirin as initial treatment for HCV genotype 2 chronic hepatitis: analysis of a large single center cohort. (updated October 28, 2006)

o       384. HCV-RNA in the fourth week as a predictive factor of sustained virological response (SVR) in genotype 1 hepatitis C patients treated with Peg-Interferon-α2b(PEG-IFN-α2b)and Ribavirin (updated October 28, 2006)

o       394. Treatment with Peginterferon alfa 2b and Ribavirin of Chronic Hepatitis C Patients on Substitution Therapy and Outcome in the Clinical Setting in Germany (updated November 8, 2006)

o       404. Pegylated Interferon alfa-2b Plus Ribavirin in Patients With Genotype 1 Chronic Hepatitis C With a Slow Virologic Response: An Early Enrollers Analysis of the SUCCESS Study (updated October 28, 2006)

o       778. Sustained Viral Response Using Peg IFN alfa-2b Plus Ribavirin in Patients with Recurrent Hepatitis C after Liver Transplantation (updated November 8, 2006)

o       1132. Risk Factors for Relapse in Genotype 3 High Viral Load Patients with Hepatitis C In the WIN-R Trial (updated November 1, 2006)

o       1138. Peginterferon alfa-2b and ribavirin for 14 or 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response. The North-C trial

o       1145. Long-term Low Dose Treatment with Pegylated Interferon alpha 2b leads to a significant Reduction in Fibrosis and Inflammatory Score in Chronic Hepatitis C Nonresponder Patients with Fibrosis or Cirrhosis (updated November 3, 2006)

 

·        Prisons

o       258. Treatment of hepatitis C (HCV) in prison settings is cost-effective: mathematical modeling of epidemiology, disease outcomes and cost-effectiveness (updated October 28, 2006)

o       345. HCV Treatment Response Rates in an Incarcerated Population-Influence of Race, Compliance and Pegylated Interferon (updated November 3, 2006)

 

·        Race

o       LB23. Rapid and Early Virologic Responses to Peginterferon Alfa-2a plus Ribavirin in Treatment-Naïve Latino vs non-Latino Caucasians Infected with HCV Genotype 1: the LATINO Study (updated November 2, 2006)

o       367. Contraction of HCV-Specific CD4+ T cell Responses in Patients Undergoing Antiviral Therapy Irrespective of Race and Virologic Outcome

 

·        Side effects

o       210. Platelet serotonine levels as predictor for the need of antidepressant treatment before and during chronic hepatitis C and interferon-alfa treatment.  

o       344. Efficacy and tolerability of citalopram in interferon-induced depression: a randomized, placebo-controlled double-blind study on the antidepressant treatment in HCV patients with antiviral therapy (updated November 1, 2006)

o       379. A Randomized Double-Blind Placebo-Controlled Trial of Paroxetine to Prevent Interferon-α-Induced Depression in Patients with Hepatitis C (updated October 28, 2006)

o       393. A Prospective, Double-Blinded Neuropsychiatric Comparison of Pegylated Interferons Alfa-2a and Alfa-2b

o       1144. Eicosapentaenoic acid Maintains Ribavirin Dose in HCV-Infected Patients who treated with the combination therapy of pegylated interferon α plus ribavirin. : A Prospective, Randomized Controlled trial